Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

197 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-08-31

Study Completion Date

2015-12-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research project consists of a prospective diagnostic study conducted on patients with clinical suspicion of rhabdomyolysis admitted to the emergency rooms of the University Hospitals of Nimes, Montpellier, Paris, Nice and Toulon Inter Army Hospital. The main objective of this study is to determine whether the plasma level of Neutrophil Gelatinase Associated Lipocalin (NGAL) may be retained as a predictor of acute renal failure (ARF) occurring within 48 hours after admission for rhabdomyolysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neutrophil Gelatinase-associated Lipocalin (NGAL) Evaluation in Emergency Department (ED) All-Comers

NCT00845741

Acute Kidney Injury

COMPLETED

Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury

NCT01122225

Acute Kidney Failure

UNKNOWN

NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure

NCT01227122

Preoperative KIDNEY FAILURE, CHRONIC Postoperative KIDNEY FAILURE, ACUTE Cardiac Surgical Procedures

UNKNOWN

Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis

NCT02049125

Acute Kidney Injury Hepatorenal Syndrome

UNKNOWN

Neutrophil Gelatinase Associated Lipocalin (NGAL) in Urine: Can This Prove to be a Biomarker for Acute Kidney Injury in Patients With Sepsis?

NCT02034240

Severe Sepsis Septic Shock Acute Kidney Injury

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The secondary objectives of this are:

* to study plasma NGAL levels on admission to the emergency ward as a marker of morbidity and mortality by considering the following factors: duration of hospitalization, need for extracorporeal blood purification, ICU admission, death.
* to study the delay between the onset of the proposed cause of rhabdomyolysis and treatment initiation
* to study the delay between treatment initiation and the occurrence of ARF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhabdomyolysis Acute Kidney Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Adult patients with suspected rhabdomyolysis admitted to the participating University Hospital emergency rooms (see inclusion/exclusion criteria).

Plasma NGAL level

Intervention Type BIOLOGICAL

The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plasma NGAL level

The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* Patient hospitalized with Creatine Phospho-Kinase \> 1000 UI/l

Exclusion Criteria

* The patient is participating in another study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* The patient is pregnant, parturient, or breastfeeding
* Chronic renal insufficiency with dialysis
* The patient has an acute coronary syndrome
* Nephrotoxic medications within 72 hours prior to admission
* Need for a procedure involving the injection of iodine
* Patient in shock
* Occurrence of acute renal failure can be explained by a cause other than rhabdomyolysis.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No